Heartflow, Inc. (HTFL) News
Follow Heartflow, Inc. (HTFL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 18 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
HeartFlow Reports Q3 Revenue of $72.9 Million, Raises 2026 Guidance
Revenue rose 57% year over year to $72.9 million. HeartFlow raised full-year revenue guidance to $262 million-$264 million; quarterly adjusted loss was $0.03 per share.
EQUITY | Nov 12, 2026, 11:03 PM UTC
M
Heartflow Reports Q3 2026 Results, Raises Full-Year Guidance
EQUITY | Nov 12, 2026, 09:22 PM UTC
M
HeartFlow Q3 Adjusted Loss Narrows as Revenue Rises; 2026 Guidance Raised
HeartFlow reported a narrower adjusted loss and higher revenue for Q3 and raised its 2026 revenue guidance.
EQUITY | Nov 12, 2026, 09:19 PM UTC
M
Heartflow CT-Guided PCI Planning Meets P4 Trial Primary Endpoint
Heartflow said its CT-guided PCI planning met the primary endpoint in the P4 trial.
EQUITY | Nov 02, 2026, 10:50 AM UTC
M
Biotech Stocks Surge to 52-Week Highs on Strong Clinical Data
Several biotech stocks reached new 52-week highs on October 5, 2026, propelled by positive clinical research data and strong Phase 3 results. Vaxcyte Inc. (PCVX) saw a significant jump of 31%, while INFU and ILMN rose 7%
EQUITY | Oct 06, 2026, 07:52 AM UTC
L
HTFL: Plaque Analysis growth and new trials drive expansion toward an $11B TAM by 2030
AI-driven coronary artery disease diagnostics are accelerating growth, with Plaque Analysis adoption and revenue surging, supported by robust clinical data and expanding payer coverage. Strategic RCTs target a $6B asympt
EQUITY | Sep 09, 2026, 09:39 PM UTC
L
HTFL: Rapid Plaque Analysis growth and new trials target a doubling of addressable market by 2029
AI-driven coronary artery disease diagnostics are seeing rapid Plaque Analysis adoption, strong revenue growth, and expanding clinical evidence. New RCTs target a $6 billion asymptomatic market, aiming to double TAM by 2
EARNINGS | Sep 09, 2026, 09:04 PM UTC
L
Heartflow price target announced at $55.00 by UBS
UBS set a price target of $55.00 per share for Heartflow.
EQUITY | Sep 09, 2026, 01:33 PM UTC
H
HTFL - Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart
HTFL - Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half
GEOPOLITICS | Aug 28, 2026, 06:57 AM UTC
L
Heartflow to participate in Wells Fargo healthcare conference
Heartflow will participate in the Wells Fargo 21st Annual Healthcare Conference.
EQUITY | Aug 27, 2026, 08:08 PM UTC
L
HTFL - Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference
HTFL - Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference
EQUITY | Aug 27, 2026, 08:01 PM UTC
L
HeartFlow shares jump after strong Q2 adjusted EPS, raised outlook
HeartFlow Inc. (HTFL) posts better-than-expected second-quarter adjusted EPS and raises full-year 2026 revenue guidance to $246 million–$250 million from $228 million–$232 million.
EARNINGS | Aug 14, 2026, 07:47 PM UTC
L
Heartflow, Eton, Nu Holdings rise on earnings and guidance
Heartflow shares jump after quarterly adjusted EPS beats estimates while revenue misses; Eton Pharmaceuticals and Nu Holdings also climb after better-than-expected quarterly results, and Eton issues FY26 revenue guidance
EARNINGS | Aug 14, 2026, 01:55 PM UTC
L
HeartFlow raises full-year revenue and margin guidance after Q2 growth
HeartFlow reported Q2 2026 revenue of $64.1 million, up 48% year over year, and raised full-year revenue guidance to $246 million-$250 million while lifting non-GAAP gross margin guidance to about 82%.
EARNINGS | Aug 13, 2026, 09:49 PM UTC
L
HeartFlow raises FY2026 sales guidance to $246M–$250M
HeartFlow (NASDAQ: HTFL) raises FY2026 sales guidance to $246.000M–$250.000M from $218.000M–$222.000M versus a $230.073M estimate.
EARNINGS | Aug 13, 2026, 08:01 PM UTC
L
Heartflow reports Q2 2026 results and raises full-year 2026 guidance
Heartflow (HTFL) reports second-quarter 2026 financial results and raises its full-year 2026 guidance, according to TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 08:01 PM UTC
H
Cantor Initiates DUOT Overweight
Banks initiate coverage on several stocks
EQUITY | Jul 31, 2026, 11:38 AM UTC
L
Freedom Capital Markets Initiates Coverage On HeartFlow with Buy Rating, Announces Price Target of $37
Freedom Capital Markets analyst Gene Mannheimer initiates coverage on HeartFlow (NASDAQ: HTFL ) with a Buy rating and announces Price Target of $37.
EQUITY | Jul 01, 2026, 08:45 AM UTC